COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 8 FDA records to the applicant name Lungpacer Medical USA, Inc.. It includes 1 original PMA approval. 6 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Dec 4, 2024 to Sep 25, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code SDL appears in 8 of the 8 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P240012, with 8 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 260 Sierra Dr., Suite 116, Exton, PA, 19341. Recorded on P240012/S008, decision dated Sep 25, 2026.
Device categories in this collection
Transvenous Temporary Phrenic Nerve Stimulator.
Changes described in PMA records
The FDA database lists decision APPR for supplement P240012/S008 to AeroPace® System, submitted by Lungpacer Medical USA, Inc., dated 2026-09-25. The supplement type is Real-Time Process with reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The source statement describes approval for changes to the temperature control components in the Neurostimulation Console and packaging changes for the Console. The product code is SDL, categorized as a transvenous temporary phrenic nerve stimulator under Anesthesiology.
The P240012 prefix links this supplement to the original PMA of that number, but a supplement is not a new approval of the whole system. The statement reports a regulatory decision on specified component and packaging changes; it does not establish safety or clinical effectiveness. Specifics absent from the record include which temperature control components changed, the nature of the packaging changes, and any supporting data.
FDA approval-order wording
Approval for changes to the temperature control components in the Neurostimulation Console and packaging changes for the Console.
Sep 25, 2026 · Real-Time ProcessFDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240012
Jun 22, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: Approval for dimensional changes to the luer connectors of the Neurostimulation Catheter.
Jun 22, 2026 · Real-Time ProcessFDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240012.
Feb 20, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: Addition of two suppliers of PCBAs included in the assembly of the Neurostimulation Console and Handheld Controller.
Jan 14, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.